Epigenetic reprogramming modulates malignant properties of human liver cancer
Chiara Raggi, Valentina M. Factor, Daekwan Seo, Agnes Holczbauer, Matthew C. Gillen, Jens U. Marquardt, Jesper B. Andersen, Marian Durkin, Snorri S. Thorgeirsson – 21 January 2014 – Reversal of DNA hypermethylation and associated gene silencing is an emerging cancer therapy approach. Here we addressed the impact of epigenetic alterations and cellular context on functional and transcriptional reprogramming of hepatocellular carcinoma (HCC) cells.